Life Sciences & Health Services

Atlas Spine, Inc.

Worked as co-placement agent in placing $3.5 million in Series A Preferred Stock for Atlas Spine, Inc. with a single institutional investor. Proceeds from the sale were allocated toward inventory, product development, workforce expansion, and general working capital.

BEI Medical Systems, Inc.*

$4.2 million PIPE for BEI Medical Systems.  Company sold in 2002 Boston Scientific for $95 million.

Catalyst Pharmaceuticals, Inc.*

Over $40 million in private & public equity financing for Catalyst Pharmaceuticals, including 2 private placements, a $20 million Nasdaq Global Market IPO on the, and 5 registered direct public offerings of common stock.

Cybear, Inc.*

Raised approximately $48,000,000 in a follow-on public offering acting as co-manager for this company delivering internet-based products and services to improve the efficiency of day-to-day administrative and communications tasks of healthcare providers.

Cytomedix, Inc. (NYSE Alternext:GTF)

Worked as the sole placement agent for Cytomedix, Inc. to raise a total of $1.47mm in common stocks with warrants via a registered direct offering with several institutional investors and current shareholders. Proceeds used for general working capital.

LifeCell Corporation*

$20.5 million secondary public offering and two PIPEs ($12.4 million and $3.9 million) for LifeCell Corporation Company sold in 2008 to Kinetic Concepts Inc. for $1.7 billion.

MedLink International, Inc. (OTCBB:MLKNA)

Worked as selling agent to Aegis Capital Corp. in placing $2.25 million in financing for MedLink International, Inc. The aggregate amount consisted of a $1.0 million placement of common stock and warrants plus a $1.25 million placement of convertible notes. Proceeds from the raise were allocated toward sales and marketing, working capital, as well as the acquisition of MedAppz, announced in November 2010.

Questcor Pharmaceuticals, Inc*

Sole managed $20 million IPO for Ribogene (Questcor). Company sold in 2014 to Mallinckrodt for $5.6 billion.

RLAB, Inc.*

Raised $13,300,000 of equity in two private placements for this generic pharmaceutical company.  Financial advisor to Royce in its merger with Watson Pharmaceuticals valued at approximately $100,000,000.  

ScripsAmerica, Inc.

Worked as sole placement agent for ScripsAmerica, Inc. to raise $1.043 million in Series A Preferred Stock via a private placement. Proceeds were used for general working capital. ScripsAmerica, Inc. implements efficient supply chain management on behalf of its clients, from strategic sourcing to delivering niche generic pharmaceuticals to market.

* Indicates transactions were completed by Avalon Net Worth senior executives while employed at previous firms

Page 1 of 2